Liminatus Pharma, Inc.
LIMN
$0.14
$0.013.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -243.11% | -3,454.79% | -203.19% | 92.12% | -163,650.00% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -- | -- | -- |
| Change in Net Operating Assets | -633.19% | 337.26% | -69.87% | -565.21% | 83,950.00% |
| Cash from Operations | -1,164.30% | -174.91% | -191.41% | -712.81% | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 100.00% | 100.00% | 48.33% | -- |
| Cash from Investing | -- | 100.00% | 98.36% | 48.33% | 17.86% |
| Total Debt Issued | -- | -100.00% | -100.00% | 93.75% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | -7,021.39% | -- |
| Cash from Financing | 402.85% | -100.00% | -100.00% | 400.58% | -38.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 7,436.45% | -4,259.14% | -4,857.36% | 420.23% | 94.75% |